Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 9Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Acute 2Sarcoma, Myeloid 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 3Mitoxantrone 2Cladribine 2venetoclax 1pegylated granulocyte colony-stimulating factor 1Sorafenib 1Razoxane 1Leyk 1Idarubicin 1Gemtuzumab 1Etoposide 1Dexrazoxane 1Daunorubicin 1Bortezomib 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Myeloid × Gemtuzumab × 90 days × Clear all
NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡